A unicorn startup or unicorn company is a private company with a valuation over $1 billion USD. Unicorns are ‘startups’, i.e they do not include post-exit, acquired or listed companies, nor do they include ‘mature’ incumbents.
As of 27 May 2021, there are 62 HealthTech Unicorns around the world who are now collectively valued at $132B+.
Aledade, EQRx, Innovaccer, ATAI Life Sciences, Brii BioSciences, Evidation Health, Ginger, Komodo Health, Radiology Partners, Rightway, Unite Us, DispatchHealth joined the list in Jan – Mar 2021.
Capsule, KRY, and Caris Life Sciences joined the list in Apr – May 2021.
Recursion Pharmaceuticals left the list in April 2021 via IPO.
Oscar Health left the list in March 2021 via IPO.
Sema4 was acquired by Casdin Capital and Corvex Management (SPAC) in February 2021.
23andMe was acquired by Virgin Galactic Acquisition Corporation (SPAC) in February 2021.
Tempus was acquired by PNC Bank in January 2021.
Clover Health left the list in January 2021 via IPO.
|Company||Country||Last Round Date||Last Round Type||Valuation|
|Samumed||United States||Apr 2019||Series C||$12.4B|
|Roivant Sciences||United States||Nov 2018||$200M PE Round||$9B|
|Caris Life Sciences||United States||May 2021||$830M PE Round||$7.83B|
|WeDoctor (GuaHao)||China||May 2018||$500M Series F||$5.5B|
|United Imaging Healthcare||China||Sep 2017||$500M Series A||$5.1B|
|Ginkgo BioWorks||United States||May 2020||$70M Series E||$4.2B|
|Radiology Partners||United States||Mar 2021||$12.6M Venture Round||$4B|
|Devoted Health||United States||Mar 2020||$450M Series C||$3.8B|
|Intarcia Therapeutics||United States||Aug 2019||Undisclosed||$3.8B|
|Komodo Health||United States||Mar 2021||$220M Series E||$3.3B|
|Grail||United States||May 2020||$390M Series D||$3.2B|
|Hinge Health||United States||Jan 2021||$300M Series D||$3B|
|BenevolentAI||United Kingdom||Sep 2019||$90M Series C||$2.1B|
|ATAI Life Sciences||Germany||Mar 2021||$157M Series D||$2B|
|Babylon Health||United Kingdom||Aug 2019||$550M Series C||$2B|
|KRY||Sweden||Apr 2021||$319M Series D||$2B|
|Oxford Nanopore Technologies||United Kingdom||May 2020||$59.2M Series G||$2B|
|Aledade||United States||Jan 2021||$100M Series D||$1.9B|
|Virta Health||United States||Apr 2021||$133M Series D||$1.9B|
|Zocdoc||United States||Aug 2015||$130M Series D||$1.8B|
|DispatchHealth||United States||Mar 2021||$200M Series D||$1.7B|
|Unite Us||United States||Mar 2021||$150M Series C||$1.7B|
|Verily||United States||Jan 2019||$1B PE Round||$1.6B|
|K Health||United States||Jan 2021||$132M Series E||$1.5B|
|Color||United States||Jan 2021||$167M Series D||$1.5B|
|HeartFlow||United States||Jun 2019||$65M Series E||$1.5B|
|Insightec||Israel||Mar 2020||$150M Series F||$1.5B|
|Ro||United States||Jul 2020||$200M Series C||$1.5B|
|Brii Biosciences||United States||Mar 2021||$155M Series C||$1.45B|
|Alzheon||United States||Sep 2020||$2.4M Venture Round||$1.31B|
|Innovaccer||United States||Feb 2021||$105M Series D||$1.3B|
|Medlinker||China||Jul 2018||$146.8M Series D||$1.25B|
|EQRx||United States||Jan 2021||$500M Series B||$1.23B|
|Lyell Immunopharma||United States||Mar 2020||$493M Series C||$1.2B|
|Modern Health||United States||Feb 2021||$74M Series D||$1.2B|
|Ginger||United States||Mar 2021||$100M Series E||$1.1B|
|Rightway||United States||Mar 2021||$100M Series C||$1.1B|
|Doctolib||France||Mar 2019||$170M Series E||$1.1B|
|Lyra Health||United States||Aug 2020||$110M Series D||$1.1B|
|Cityblock Health||United States||Mar 2021||$192M Series C||$1B|
|Miaoshou Doctor||China||Jun 2020||$84.7M Series D||$1B|
|Capsule||United States||Apr 2021||$300M Series D||$1B|
|Evidation Health||United States||Mar 2021||$153M Series E||$1B|
|Modernizing Medicine||Switzerland||May 2017||$231M PE Round||$1B|
|Alto Pharmacy||United States||Jan 2020||$250M Series D||$1B|
|Aprogen||South Korea||May 2019||–||$1B|
|Bright Health||United States||Sep 2020||$500M Series E||$1B|
|Calm||United States||Jul 2019||$27M Series B||$1B|
|CMR Surgical||United Kingdom||Sep 2019||$240M Series C||$1B|
|DXY||China||Apr 2018||$100M Series D||$1B|
|Gympass||United States||Jun 2019||$300M Series D||$1B|
|iCarbonX||China||Jun 2018||$141.77M Series A||$1B|
|Keep||China||May 2020||$80M Series E||$1B|
|LinkDoc||China||Jul 2018||$151M Series D||$1B|
|OrCam||Israel||Feb 2018||$30.4M VC Round||$1B|
|Orca Bio||United States||Jun 2020||$192M Series D||$1B|
|PointClickCare||Canada||Feb 2018||$146M Series D||$1B|
|Rani Therapeutics||United States||Feb 2018||$53M||$1B|
|VillageMD||United States||Jul 2020||$275M VC Round||$1B|
|Zwift||United States||Sep 2020||$450M Series C||$1B|
$30B of private funding in 5 Years fueling the future of post-secondary learning and earning.
The Complete List of Global EdTech Unicorns
The Complete List of Global HealthTech Unicorns
Q1 delivered nearly $4B of Global EdTech Venture Capital, on track to meet the 2020 record of $16.1B. The US has already deployed $1B for 2021, challenging the $2.5B total for 2020. Strong starts all around the world.